Cambridge Healthtech Institute’s 21st Annual
Engineering Antibodies
May 6-7, 2020
The field of protein engineering is at an exciting point in its development, with new generations of therapeutic antibodies now progressing through development and into the market, great advances in protein science and discovery technology, and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs. The PEGS Engineering Antibodies conference explores case examples of the most significant emerging discovery and informatics technologies used by protein engineers working at the discovery and design stages to quickly and efficiently craft biotherapeutics directed at the most elusive targets and biological functions.
Preliminary Agenda
APPLICATIONS OF MACHINE LEARNING IN BIOTHERAPEUTIC R&D
Applying Machine Learning to Improve Protein Expression and Solubility
Erik Vernet, PhD, Director, Protein Engineering, Novo Nordisk Research Center Seattle
Design of Proteins and Antibodies Using Machine Learning
Philip Kim, PhD, Associate Professor, Molecular Genetics, University of Toronto
KEYNOTE PRESENTATION: Machine Learning-Based Antibody Discovery
David Gifford, PhD, Professor, Computer Science and Biological Engineering, MIT
IMPROVING TARGETING SPECIFICITY
Design of Exquisite Binding Specificity
Shohei Koide, PhD, Professor, Biochemistry and Molecular Pharmacology, NYU
A Novel Mammalian Display Platform for the Engineering of Highly Specific T Cell Receptors
Rodrigo Vazquez-Lombardi, PhD, Postdoctoral Fellow, Biosystems Science and Engineering, ETH Zurich, Switzerland
Engineering Acidic pH Selective mAbs Targeting VISTA
Julie Su, PhD, Senior Research Investigator, Molecular Discovery Technologies, Bristol Myers Squibb
SUBCELLULAR AND INTRACELLULAR TARGETING
Subcellular Trafficking Pathways as Targets for the Design of Therapies for Autoimmunity and Cancer
Sally Ward, PhD, Professor, Molecular Immunology, University of Southampton, United Kingdom
Developing Therapeutics for Intracellular Targets
Francois-Thomas Michaud, PhD, CEO, Feldan Therapeutics
OVERCOMING LIABILITIES
Presentation of Non-Germline Residues and Clinical Consequences: A Case Study
Nicoletta Bivi, PhD, Director, Assay Development, Immunogenicity and Immunoassays, Laboratory for Experimental Medicine (LEM), Eli Lilly and Company
Molecular Design Intent in Early Drug Discovery
Carlos R. Reis, PhD, Team Leader, Molecular Design and Engineering, GlaxoSmithKline, United Kingdom
CHALLENGES AND SOLUTIONS
Next-Generation Technologies for Antibody Library Design and Screening
Brandon DeKosky, PhD, Assistant Professor, Chemical Engineering, University of Kansas
A High-Throughput Production Workflow for Complex Format Therapeutic Molecules
Avinash Gill, PhD, Senior Scientific Manager, Genentech
LUNCHEON PRESENTATION I: Lessons in Generating Monoclonal Antibodies against Multipass Membrane Proteins
Ross Chambers, PhD, Vice President, Antibody Discovery, Integral Molecular
Antibody Protein Sequencing with Mass Spectrometry
Anthony Stajduhar, Business Development Manager, Sales, Rapid Novor, Inc.
* The program is subject to change without notice, due to unforeseen reason.
Sponsor updated
2020 PROGRAMS
View By:









Emerging Indications for Therapeutic Antibodies
Immunogenicity Case Studies and Clinical Management
Improving Immunotherapy Efficacy and Safety
Engineering Antibody-Drug Conjugates
Gene Therapy: Advancing from Bench to Clinic
Immunogenicity Assessment and Regulatory Approval of Biologics
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
Optimizing Bioassays for Biologics
Clinical Progress of Antibody-Drug Conjugates
Characterization for Novel Biotherapeutics
Cell and Gene Therapy Analytics
Engineering Bispecific Antibodies
Protein Expression System Engineering